Eligible, But Probably Obvious: Prometheus Patents Critiqued In Government's Amicus Brief
This article was originally published in The Pink Sheet Daily
Executive Summary
The Solicitor General tells the Supreme Court that Prometheus' patents on a process for determining the proper dose of thiopurine drugs should have included "concrete treatment steps."
You may also be interested in...
Drug Calibration Patents Under Scrutiny As Supreme Court Weighs How To Build On Law Of Nature
During oral arguments in Mayo v. Prometheus, justices question what standard to apply in assessing whether the correlation of a drug’s metabolites to proper dosage is patentable; ACLU petitions court to review Myriad gene patent case.
Personalized Medicine At Stake In Prometheus Patent Case, BIO Tells Supreme Court
The biotech and pharmaceutical industries oppose a broad ruling that would prevent patenting of medical processes and diagnostics. Mayo is challenging patents on the correlation between drug metabolites and proper dosage.
Supreme Court To Consider Prometheus Patents On Method Of Calibrating Drug Dosage
Mayo contends Prometheus patents cover a natural phenomenon.